TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 181.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,614 shares of the biopharmaceutical company’s stock after purchasing an additional 15,238 shares during the period. SG Americas Securities LLC’s holdings in TG Therapeutics were worth $552,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TGTX. Quarry LP grew its stake in TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 503 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of TG Therapeutics by 3.9% in the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock worth $538,000 after buying an additional 1,322 shares during the last quarter. Swiss National Bank raised its holdings in TG Therapeutics by 0.5% in the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock valued at $4,321,000 after acquiring an additional 1,500 shares in the last quarter. nVerses Capital LLC boosted its stake in TG Therapeutics by 34.9% during the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in TG Therapeutics by 3.9% during the 2nd quarter. Arizona State Retirement System now owns 41,069 shares of the biopharmaceutical company’s stock worth $731,000 after acquiring an additional 1,539 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TGTX has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $49.00 target price on shares of TG Therapeutics in a research note on Wednesday, September 18th. B. Riley increased their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group lifted their target price on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.

TG Therapeutics Stock Up 7.6 %

Shares of TG Therapeutics stock opened at $24.57 on Wednesday. The stock has a market capitalization of $3.80 billion, a price-to-earnings ratio of 106.83 and a beta of 2.21. TG Therapeutics, Inc. has a twelve month low of $6.46 and a twelve month high of $26.41. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The business’s 50 day simple moving average is $22.95 and its 200-day simple moving average is $19.19.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The firm’s quarterly revenue was up 357.0% compared to the same quarter last year. During the same period last year, the business posted ($0.34) earnings per share. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.